Checkpoint Inhibition for Metastatic Urothelial Carcinoma After Chemotherapy—Real-World Clinical Impressions and Comparative Review of the Literature
Background: The introduction of checkpoint inhibitors is a long-awaited new option for a urothelial cancer with a poor prognosis. Apart from clinical studies, the data on real world experience is scarce.Methods: Patients for monotherapy with either Atezolizumab, Nivolumab or Pembrolizumab after chem...
Sábháilte in:
| Príomhchruthaitheoirí: | , , , , , , , , , , |
|---|---|
| Formáid: | Artigo |
| Teanga: | Inglês |
| Foilsithe / Cruthaithe: |
Frontiers Media S.A.
2020-05-01
|
| Sraith: | Frontiers in Oncology |
| Ábhair: | |
| Rochtain ar líne: | https://www.frontiersin.org/article/10.3389/fonc.2020.00808/full |
| Clibeanna: |
Níl clibeanna ann, Bí ar an gcéad duine le clib a chur leis an taifead seo!
|